Drug intelligence / Profile preview

DW-4222

Development stage: Preclinical
Lead developer: Daewon Pharm
Modality: Small Molecules
Administration: Oral

Overview

DW-4222 is an orally bioavailable small molecule GLP-1 receptor agonist currently in preclinical development for the treatment of obesity. Developed by Daewon Pharm in collaboration with Asan Medical Center, the drug aims to provide a more convenient oral alternative to the widely used injectable peptide-based GLP-1 therapies. By activating the GLP-1 receptor, DW-4222 is intended to regulate appetite and glucose metabolism, facilitating weight loss in patients with obesity. The program was licensed from Asan Medical Center (Asan Foundation) to Daewon Pharm for further development and commercialization.

Targets

PON2 (Paraoxonase 2)

Beyond the preview

Go deeper on DW-4222.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DW-4222.

Explore the full profile